Ovid Therapeutics has recently captured investor attention with a remarkable 700% rally in its stock price. This surge has raised questions about the company's valuation and future prospects.
Despite this impressive increase, analysts suggest that the stock may still be undervalued when considering risk-adjusted metrics. This indicates potential opportunities for savvy investors.
As the market continues to evolve, understanding the underlying valuation of Ovid Therapeutics will be crucial for making informed investment decisions.